BioLineRx

From Wikipedia, the free encyclopedia

Template:Advert

Page Module:Infobox/styles.css has no content.Page Template:Infobox company/styles.css has no content.

BioLineRx Ltd.
Company type
Public
Nasdaq: BLRX
TASE: BLRX
ISINScript error: No such module "WikidataIB".
IndustryScript error: No such module "WikidataIB".
PredecessorScript error: No such module "WikidataIB".
IncorporatedScript error: No such module "WikidataIB".
FoundedScript error: No such module "WikidataIB".
FounderScript error: No such module "WikidataIB".
DefunctScript error: No such module "WikidataIB".
SuccessorScript error: No such module "WikidataIB".
Headquarters
Modiin
,
Israel
Key people
Philip Serlin (CEO)
ServicesDrug development
RevenueScript error: No such module "WikidataIB".
Script error: No such module "WikidataIB".
Script error: No such module "WikidataIB".
Total assetsScript error: No such module "WikidataIB".
OwnersNovartis (12.8%, 2014)
Number of employees
Script error: No such module "WikidataIB".
Websitewww.biolinerx.com
Footnotes / references
[1][2]

Script error: No such module "Check for conflicting parameters".Script error: No such module "Check for deprecated parameters".

File:Hotzvimview.jpg
BioLineRX office in Har Hotzvim Technology Park, Jerusalem

BioLineRx Ltd. (Template:Langx), or BioLine, is a publicly traded drug development company. Headquartered in Israel, its shares are traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange.

Corporate history

The firm was established in 2003 as a joint venture of Teva, Hadasit Bio-Holdings, the Jerusalem Development Authority, Yehuda Zisapel, and other investors.[3] It executed an initial public offering on the Tel Aviv Stock Exchange in February 2007, raising 211 million NIS ($50 million) – the TASE's largest biotech IPO until that time.[4][5] In July 2011 BioLine's ADRs began trading on the NASDAQ Capital Market.[6][7] In January 2012, the firm announced a deal with Genoscience, a French pharmaceutical company to jointly develop and market the BL-8020 compound, as a treatment for Hepatitis C.[8] At the end of 2014, Novartis acquired a 12.8% stake in the company as a strategic move to gain access to Israeli-sourced drug candidates.[2]

Management

Morris Laster, (M.D.) an alumnus of. Downstate Medical Center, was CEO of BioLineRx until 2009. He was replaced by Kinneret Savitsky, alumnus of Tel Aviv University early in 2010.[9] Savitsky was replaced as CEO by BioLine COO Philip Serlin on October 10, 2016.

Operations

File:BioLineRx.png
Previous logo

BioLineRx is a drug development company When promising compounds are discovered, the firm leads them through preclinical trials and engages other companies to further develop them into commercializable drugs.[10] The company entered into its first major commercialization agreement in 2009 when it partnered with Ikaria Holdings Inc. to develop its BL-1040 compound.[11] In 2010, BioLine entered into a commercialization agreement with Cypress Bioscience Inc. for development of its BL-1020 compound. The agreement with Cypress was canceled in 2011 when the company was taken over by Ramius LLC.[12]

Pipeline

Below is a partial list of drug compounds in various stages of development by BioLineRx. Unless indicated otherwise, they have not obtained regulatory approval in relation to the diseases cited.

See also

References

Page Template:Reflist/styles.css has no content.

  1. ^ Page Module:Citation/CS1/styles.css has no content."BLRX Profile: BioLineRx Ltd. Stock". Yahoo! Finance. 2011. Retrieved 28 November 2011.
  2. ^ a b Page Module:Citation/CS1/styles.css has no content."Novartis Makes $10M Investment in BioLineRx". Industry Watch. Genetic Engineering & Biotechnology News. Vol. 35, no. 2. 16 December 2014. p. 9.
  3. ^ Page Module:Citation/CS1/styles.css has no content.Grayeff, Yigal (13 January 2005). "BioLineRx signs 3 deals to develop drugs". The Jerusalem Post. Archived from the original on 3 February 2010. Retrieved 28 November 2011 – via IVC Research Center.
  4. ^ Page Module:Citation/CS1/styles.css has no content.Cohen, Omri (7 February 2007). "Biotech comes of age: Bioline floats at half-billion shekel market cap". TheMarker. Archived from the original on February 21, 2015. Retrieved 28 November 2011. Bioline Therapeutics today pulled off its initial public offering in Tel Aviv, raising NIS 211 million at a company valuation of NIS 494 million, making this the biggest flotation by a biotechnology company in local history.
  5. ^ Page Module:Citation/CS1/styles.css has no content.Rheinheimer, Laura (8 February 2007). "BioLineRx raises $50m. in TASE's largest biomedical IPO". The Jerusalem Post. Retrieved 28 November 2011. BioLineRx Ltd. on Wednesday priced the largest ever initial public offering of a biomedical company on the Tel Aviv Stock Exchange, raising a total of NIS 211 million, or $50m.
  6. ^ Page Module:Citation/CS1/styles.css has no content."BioLineRx ADRs Begin Trading on NASDAQ". 25 July 2011. Retrieved 27 April 2019.
  7. ^ Page Module:Citation/CS1/styles.css has no content.Cohen, Tova (24 July 2011). Magnowski, Daniel (ed.). "BioLineRX ADRs to begin trading on Nasdaq Monday". Reuters. Archived from the original on 24 September 2015. Retrieved 30 June 2017.
  8. ^ Page Module:Citation/CS1/styles.css has no content.Wang, Lu (24 January 2012). "Achillion, BioLineRx, J&J Snack, Rubicon: U.S. Equity Movers". Bloomberg News. Archived from the original on 24 January 2012.
  9. ^ Page Module:Citation/CS1/styles.css has no content."Kinneret Livnat Savitsky Ph.D.: Executive Profile & Biography". Bloomberg Business. Retrieved 21 February 2015.
  10. ^ Page Module:Citation/CS1/styles.css has no content.Brinn, David (3 June 2007). "BioLineRx—Israel's biotech supermarket". ISRAEL21c. Archived from the original on 5 April 2012. Retrieved 28 November 2011.
  11. ^ Page Module:Citation/CS1/styles.css has no content.Habib-Valdhorn, Shiri (28 April 2010). "BiolineRX earns $10m milestone payment". Globes. Retrieved 28 November 2011.{{cite news}}: CS1 maint: deprecated archival service (link)
  12. ^ Page Module:Citation/CS1/styles.css has no content.Weinreb, Gali (11 May 2011). "BiolineRX and Cypress cancel schizophrenia drug agreement". Globes. Archived from the original on 15 June 2011. Retrieved 28 November 2011.
  13. ^ Page Module:Citation/CS1/styles.css has no content."BioLineRx In-Licenses Novel Compound for Treatment of Neuropathic Pain". Archived from the original on 2015-09-26.
  14. ^ Page Module:Citation/CS1/styles.css has no content."Israeli co to hold clinical trial for treatment of Schizophrenia in India". The Hindu Business Line. Jerusalem. 24 November 2011. Retrieved 28 November 2011.
  15. ^ Page Module:Citation/CS1/styles.css has no content.BioLineRx (13 September 2011). "BioLineRx Announces Positive Preliminary Results from Phase I Clinical Trial of BL-1021 for Neuropathic Pain" (Press release). Jerusalem. Retrieved 28 November 2011 – via Business Wire.
  16. ^ Page Module:Citation/CS1/styles.css has no content."Bioline looks to heart attack treatment clinical trial". Globes. 27 February 2011. Retrieved 28 November 2011.{{cite news}}: CS1 maint: deprecated archival service (link)
  17. ^ Page Module:Citation/CS1/styles.css has no content."US company buys exclusive license for Israeli heart attack drug for $285 million". Israel21c. 8 July 2009. Retrieved 28 November 2011.
  18. ^ Page Module:Citation/CS1/styles.css has no content."Other". www.biolinerx.com. Archived from the original on 2016-12-02.
  19. ^ Page Module:Citation/CS1/styles.css has no content.Wrobel, Sharon (15 September 2011). "Bioline RX Gets European Device Confirmation for Bl-5010 Drug". Bloomberg. Retrieved 28 November 2011.
  20. ^ Page Module:Citation/CS1/styles.css has no content."BioLineRx has acquired the rights to compound BL-7040 from Yissum and Prof. Soreq". The Hebrew University of Jerusalem. The Edmond and Lily Safra Center for Brain Sciences. 27 June 2011. Archived from the original on 12 July 2011. Retrieved 28 November 2011.
  21. ^ Page Module:Citation/CS1/styles.css has no content."BioLineRx signs pact with Genoscience & RFS Pharma to develop and commercialize BL-8030 to treat hepatitis C". Pharmabiz.com. Jerusalem, Israel. 8 February 2012. Archived from the original on 21 February 2015. Retrieved 8 February 2012.

Lua error in package.lua at line 80: module 'Module:Navbox/configuration' not found.

Retrieved from "https://cosmopedia.co/index.php?title=BioLineRx&oldid=10575906"